Learn More
380 Background: PAZ, an oral multikinase inhibitor, demonstrated significant improvement in PFS over placebo in patients with aRCC in a randomized, phase III trial (J Clin Oncol 2009:29; 475). The(More)
Background: Platinum-based chemotherapy combinations are the standard of care in first-line treatment of advanced NSCLC. Maintenance therapy with a chemotherapeutic agent (continuation maintenance)(More)